Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One pill a day could slash stroke risk in ghana

NCT ID NCT05963568

Disease control Sponsor: Northern California Institute of Research and Education Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study tests whether a single daily polypill (combining blood pressure, cholesterol, and anti-clotting drugs) can help recent stroke survivors in Ghana avoid future strokes or heart attacks. About 500 participants will take the polypill or receive usual care for 24 months. The goal is to see if the polypill improves control of key risk factors and is practical for use in low-resource settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Above the age of 18 years; male or female * Ischemic stroke diagnosis no greater than two months before enrollment. Ischemic strokes including� lacunar, large-vessel atherosclerotic, cardio-embolic subtypes are eligible * Subjects with stroke may present with at least one of the following additional conditions: Documented diabetes mellitus or previous treatment with oral hypoglycemic or insulin; documented hypertension \>140/90mmHg or previous treatment with antihypertensive medications; Mild to moderate renal dysfunction (eGFR 60-30ml/min/1.73m2); Prior myocardial infarction * Legally competent to sign informed consent. Exclusion Criteria: * Unable to sign informed consent * Contraindications to any of the components of the polypill * Hemorrhagic stroke * Severe cognitive impairment/dementia or severe global disability limiting the capacity of self-care * Severe congestive cardiac failure (NYHA III-IV) * Severe renal disease, eGFR \<30ml/min/1.73m2), renal dialysis; awaiting renal transplant or transplant recipient * Cancer diagnosis or treatment in past 2 years * Need for oral anticoagulation at the time of randomization or planned in the future months; * Significant arrhythmias (including unresolved ventricular arrhythmias or atrial fibrillation) * Nursing/pregnant mothers * Do not agree to the filing, forwarding and use of his/her pseudonymized data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke Medication Adherence stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Medication adherence Stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aga Khan Hospital

    NOT_YET_RECRUITING

    Dar es Salaam, Tanzania

  • Kwame Nkrumah Institute of Science & Technology

    ACTIVE_NOT_RECRUITING

    Kumasi, Ghana

  • University Teaching Hospital of Parakou

    RECRUITING

    Parakou, Benin

  • University of Ilorin Teaching Hospital

    RECRUITING

    Ilorin, Nigeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.